These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32785219)

  • 21. Over-the-counter triptans--making the switch.
    Lancet Neurol; 2005 Oct; 4(10):587. PubMed ID: 16168921
    [No Abstract]   [Full Text] [Related]  

  • 22. The early access to medicines scheme.
    Bates S
    Br J Hosp Med (Lond); 2014 Aug; 75(8):424-5. PubMed ID: 25111091
    [No Abstract]   [Full Text] [Related]  

  • 23. What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvements.
    Miletic N; Adam S; Acquah J; Aziz Z; Joos A; Mwangi JM
    Front Med (Lausanne); 2023; 10():1207954. PubMed ID: 37731723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Healthcare professionals and the DEA: trying to get back in balance.
    Heit HA
    Pain Med; 2006; 7(1):72-4. PubMed ID: 16533201
    [No Abstract]   [Full Text] [Related]  

  • 25. Homoeopathy: not a matter for drug-regulatory authorities.
    Garattini S; Bertelé V
    Lancet; 2009 Nov; 374(9701):1578-80. PubMed ID: 19674776
    [No Abstract]   [Full Text] [Related]  

  • 26. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
    Bird RC
    J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: Ensuring patient access to essential medicines while minimizing harmful use: a revised World Health Organization tool to improve national drug control policy. Letter to the editor.
    Radbruch L; Jünger S; Mantel-Teeuwisse A; Gilson A; Cleary J; Payne S; Scholten W
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):200-1. PubMed ID: 22616835
    [No Abstract]   [Full Text] [Related]  

  • 28. Reliance: a smarter way of regulating medical products - The IPRP survey.
    Doerr P; Valentin M; Nakashima N; Orphanos N; Santos G; Balkamos G; Saint-Raymond A
    Expert Rev Clin Pharmacol; 2021 Feb; 14(2):173-177. PubMed ID: 33355025
    [No Abstract]   [Full Text] [Related]  

  • 29. The European Medicines Agency facilitates access to medicines in low- and middle-income countries.
    Cavaller Bellaubi M; Harvey Allchurch M; Lagalice C; Saint-Raymond A
    Expert Rev Clin Pharmacol; 2020 Mar; 13(3):321-325. PubMed ID: 32053756
    [No Abstract]   [Full Text] [Related]  

  • 30. Pain management: Texas legislative and regulatory update.
    Ralston DL
    J Law Med Ethics; 1996; 24(4):328-37. PubMed ID: 9180518
    [No Abstract]   [Full Text] [Related]  

  • 31. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative.
    Cherny NI; Baselga J; de Conno F; Radbruch L
    Ann Oncol; 2010 Mar; 21(3):615-626. PubMed ID: 20176694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Innovative medicines: new regulatory procedures for the third millennium.
    Rasi G; Bonini S
    Expert Opin Biol Ther; 2015; 15 Suppl 1():S5-8. PubMed ID: 25777774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regional regulatory harmonisation initiatives: Their potential contribution to the newly established African Medicines Agency.
    Ngum N; Ndomondo-Sigonda M; Walker S; Salek S
    Regul Toxicol Pharmacol; 2023 Dec; 145():105497. PubMed ID: 37778434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. African Medicines Agency to be established.
    Makoni M
    Lancet; 2021 Oct; 398(10310):1475. PubMed ID: 34688361
    [No Abstract]   [Full Text] [Related]  

  • 35. Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitude.
    Ehmann F; Papaluca Amati M; Salmonson T; Posch M; Vamvakas S; Hemmings R; Eichler HG; Schneider CK
    Clin Pharmacol Ther; 2013 May; 93(5):425-32. PubMed ID: 23549149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Harmonization of medical products regulation: a key factor for improving regulatory capacity in the East African Community.
    Ndomondo-Sigonda M; Miot J; Naidoo S; Masota NE; Ng'andu B; Ngum N; Kaale E
    BMC Public Health; 2021 Jan; 21(1):187. PubMed ID: 33478421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is India ready to lead the battle for fair access to medicines?
    Lancet Oncology
    Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313
    [No Abstract]   [Full Text] [Related]  

  • 38. A global update on the development of palliative care services.
    Morris C
    Int J Palliat Nurs; 2011 Oct; 17(10):472, 474, 476. PubMed ID: 22068116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process.
    Liberti L; Breckenridge A; Eichler HG; Peterson R; McAuslane N; Walker S
    Clin Pharmacol Ther; 2010 Jan; 87(1):27-31. PubMed ID: 20019699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.
    Smolen JS; Boers M; Abadie EC; Breedveld FC; Emery P; Bardin T; Goel N; Ethgen DJ; Avouac BP; Dere WH; Durez P; Matucci-Cerinic M; Flamion B; Laslop A; Lekkerkerker FJ; Miossec P; Mitlak BH; Ormarsdóttir S; Paolozzi L; Rao R; Reiter S; Tsouderos Y; Reginster JY;
    Curr Med Res Opin; 2011 Feb; 27(2):315-25. PubMed ID: 21142618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.